These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 29673111)

  • 1. Comparison of epidemiological features, clinicopathological features, and treatments between premenopausal and postmenopausal female breast cancer patients in western China: a retrospective multicenter study of 15,389 female patients.
    Feng F; Wei Y; Zheng K; Li Y; Zhang L; Wang T; Zhang Y; Li H; Ren G; Li F
    Cancer Med; 2018 Jun; 7(6):2753-2763. PubMed ID: 29673111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Clinicopathological Features and Treatments between Young (≤40 Years) and Older (>40 Years) Female Breast Cancer Patients in West China: A Retrospective, Epidemiological, Multicenter, Case Only Study.
    Wang K; Ren Y; Li H; Zheng K; Jiang J; Zou T; Ma B; Li H; Liu Q; Ou J; Wang L; Wei W; He J; Ren G
    PLoS One; 2016; 11(3):e0152312. PubMed ID: 27031236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinicopathological features and treatments between pre- and postmenopausal female breast cancer patients - a retrospective study.
    Kocaöz S; Korukluoğlu B; Parlak Ö; Doğan HT; Erdoğan F
    Prz Menopauzalny; 2019 Jun; 18(2):68-73. PubMed ID: 31485202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proportion of premenopausal and postmenopausal breast cancers attributable to known risk factors: Estimates from the E3N-EPIC cohort.
    Dartois L; Fagherazzi G; Baglietto L; Boutron-Ruault MC; Delaloge S; Mesrine S; Clavel-Chapelon F
    Int J Cancer; 2016 May; 138(10):2415-27. PubMed ID: 26756677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of hormone-related characteristics and breast cancer risk by estrogen receptor/progesterone receptor status in the shanghai breast cancer study.
    Bao PP; Shu XO; Gao YT; Zheng Y; Cai H; Deming SL; Ruan ZX; Su Y; Gu K; Lu W; Zheng W
    Am J Epidemiol; 2011 Sep; 174(6):661-71. PubMed ID: 21768404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II.
    Fortner RT; Eliassen AH; Spiegelman D; Willett WC; Barbieri RL; Hankinson SE
    Breast Cancer Res; 2013 Mar; 15(2):R19. PubMed ID: 23497468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression.
    Yeo W; Ueno T; Lin CH; Liu Q; Lee KH; Leung R; Naito Y; Park YH; Im SA; Li H; Yap YS; Lu YS;
    Breast Cancer Res Treat; 2019 Oct; 177(3):549-559. PubMed ID: 31270763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of breast cancer patients in Korea in 2000.
    Ahn SH;
    Arch Surg; 2004 Jan; 139(1):27-30; discussion 31. PubMed ID: 14718270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer.
    Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The diverse distribution of risk factors between breast cancer subtypes of ER, PR and HER2: a 10-year retrospective multi-center study in China.
    Song Q; Huang R; Li J; Fan J; Zheng S; Zhang B; Yang H; Tang Z; He J; Xie X; Li H; Li J; Qiao Y
    PLoS One; 2013; 8(8):e72175. PubMed ID: 23977244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor positive operable breast cancer: does menopausal status impact on HER2 and progesterone receptor status?
    Wang N; Wang B; Wang Y; Hu J
    Breast; 2011 Dec; 20(6):519-24. PubMed ID: 21700456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer.
    Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N;
    Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.
    Zhou C; He Jj; Li J; Fan Jh; Zhang B; Yang Hj; Xie Xm; Tang Zh; Li H; Li Jy; Wang Sl; Qiao Yl; Huang R; Zhang P
    PLoS One; 2014; 9(7):e100159. PubMed ID: 25036532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneity of epidemiological factors by breast tumor subtypes in Korean women: a case-case study.
    Song N; Choi JY; Sung H; Chung S; Song M; Park SK; Han W; Lee JW; Kim MK; Yoo KY; Ahn SH; Noh DY; Kang D
    Int J Cancer; 2014 Aug; 135(3):669-81. PubMed ID: 24916400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of the Interaction Between Mammographic Breast Density, Body Mass Index, and Menopausal Status With Breast Cancer Risk Among Korean Women.
    Tran TXM; Moon SG; Kim S; Park B
    JAMA Netw Open; 2021 Dec; 4(12):e2139161. PubMed ID: 34940866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationships between epidemiological features and tumor characteristics of breast cancer.
    Dogan L; Kalaylioglu Z; Karaman N; Ozaslan C; Atalay C; Altinok M
    Asian Pac J Cancer Prev; 2011; 12(12):3375-80. PubMed ID: 22471484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of breast cancer subtypes and body mass index.
    Petekkaya I; Sahin U; Gezgen G; Solak M; Yuce D; Dizdar O; Arslan C; Ayyildiz V; Altundag K
    Tumori; 2013; 99(2):129-33. PubMed ID: 23748802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.